Neovascular glaucoma (NVG) is a severely blinding disease with high intraocular pressure (IOP) resistant to treatment. The main problem in NVG is the release of vascular endothelial growth factor (VEGF) due to retinal ischemia caused by the underlying disease. Both the underlying disease and intraocular pressure should be treated in management of patients with NVG. The purpose of this review is to discuss etiology, pathogenesis, clinic classification and management of NVG. The main purpose in NVG management is to prevent the development of NVG by treating the underlying cause mainly proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO) and ocular ischemic syndrome (OIS). If NVG has developed, then it will be necessary to both treat the underlying etiology and high intraocular pressure. Panretinal photocoagulation (PRP) and anti-VEGF drugs are important in the treatment of NVG. Anti-glaucomatous drugs that reduce the production of aqueous are used in medical treatment in the control of IOP. Medical treatment may be insufficient in the control of IOP. Surgical methods will be required when IOP is not controlled by medical therapy. Fibrosis that develop after trabeculectomy and tube shunt surgeries reduces the success of surgery. Applying preoperative anti-VEGF may increase the rate of surgical success. Cyclodestructive procedures should be preferred when other surgical methods fail and patients with poor visual prognosis.
Anti-VEGF, central retinal vein occlusion, neovascular glaucoma, proliferative diabetic retinopathy